Overview
The purpose of this study is to learn about the safety and effectiveness (how well the study treatment works) of the study medicine (CIBINQO) for the potential treatment of atopic dermatitis in people under Japanese medical practice.
Eligibility
Inclusion Criteria:
- Participants receiving this Product for treatment of AD.
- Participants start receiving this Product (commercial product) for the first time and no earlier than the contract date of this Study, or Participants who continues to receive this drug after hospital transfer can be registered retrospectively.
Exclusion Criteria:
- Participants previously enrolled in this Study at the same site.